New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response

Petros Grivas: Trial is open and we look for more sites!

Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC

John Hennessy: If you have heard about time toxicity in oncology care, this manuscript shows a great example

Erman Akkus: Pancreatic cancer clinical trials in AACR24

Piotr Wysocki: Cetuximab monotherapy maintenance after FOLFIRI may not be the optimal choice but can be considered in selected mCRC patients

Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM

Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure

Samantha Tamburro: This year’s Nursing Program was such an impactful experience for my first time in-person at the NCCN Annual Conference

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma